Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | FPR3 | P25089 | 1/20 | 0.38 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | GLS | O94925 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.35 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.35 |
| ▸ | TGFBR1 | P36897 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21183561 | 0.91 | NAMPT (0.39) | KDM4EPKMEPHX1HPGDGLS | |
| SCHEMBL21176384 | 0.89 | KDM4E (0.46) | KDM4EPKMEPHX1HPGDFPR3 | |
| SCHEMBL21176260 | 0.86 | KDM4E (0.34) | KDM4EEPHX1POLBMEN1KMT2A | |
| SCHEMBL21176171 | 0.84 | KDM4E (0.44) | KDM4EPKMEPHX1HPGDFPR3 | |
| SCHEMBL21176247 | 0.83 | KDM4E (0.48) | KDM4EPKMEPHX1HPGDFPR3 | |
| SCHEMBL21176200 | 0.81 | KDM4E (0.45) | KDM4EPKMEPHX1HPGDFPR3 | |
| SCHEMBL19975179 | 0.79 | KDM4E (0.35) | KDM4EEPHX1POLBKMT2A | |
| SCHEMBL19982894 | 0.78 | KDM4E (0.42) | KDM4EPKMEPHX1HPGDFPR3 | |
| SCHEMBL21176196 | 0.76 | KDM4E (0.47) | KDM4EPKMEPHX1FPR3FPR2 | |
| SCHEMBL21176275 | 0.76 | NAMPT (0.38) | KDM4EPKMEPHX1FPR3FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | HAPLOGEN GMBH (AT) | 2022-11-10 | — | — | US | disclosed |
| US-11091428-B2 | Antiviral compounds | HAPLOGEN GMBH (AT) | 2021-08-17 | — | — | US | disclosed |
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | LUNIS CONSULTING GMBH (AT) | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190225575-A1 | ANTIVIRAL COMPOUNDS | PLA2G1B, PLA2G12A, PLA2G4C | KDM4E 3330/4885PKM 2897/4885EPHX1 372/4885 |
| US-20220356148-A1 | ANTIVIRAL COMPOUNDS | PLA2G12A, PLA2G1B, PLA2G4C | KDM4E 3784/4885PKM 3299/4885EPHX1 449/4885 |
| US-11091428-B2 | Antiviral compounds | PLA2G1B, PLA2G12A, PLA2G4C | KDM4E 3330/4885PKM 2897/4885EPHX1 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.